CD47型
癌细胞
免疫系统
癌症免疫疗法
癌症研究
化学
癌症
化学免疫疗法
吞噬作用
细胞毒性T细胞
免疫疗法
免疫检查点
免疫学
生物
医学
体外
生物化学
内科学
作者
Yehong Tan,Hanhua Chen,Jie Zhang,Linxiang Cai,Suxing Jin,Dongfan Song,Tao Yang,Zijian Guo,Xiaoyong Wang
标识
DOI:10.1016/j.ejmech.2021.114047
摘要
Phagocytosis of cancer cells by antigen presenting cells (APCs) is critical to activate the host's immune responses. However, the targeting ability of APCs to cancer cells is limited by the upregulation of transmembrane protein CD47 on the cancer cell surface. Blocking CD47 can affect the macrophage-mediated phagocytosis. Two platinum-based immunomodulators MUP and DMUP were synthesized to enhance the phagocytic activity of macrophages by blocking the CD47-SIRPα axis. These PtIV complexes not only showed high antiproliferative activity against a panel of human cancer cell lines, but also cooperated with human peripheral blood mononuclear cells (PBMCs) to suppress cancer cells. They acted as immune checkpoint inhibitors to modulate the immune responses of both cancer and immune cells. In particular, DMUP decreased the expression of CD47 in tumor tissues and promoted the polarization of macrophages from M2 to M1 phenotype in a mouse model of non-small cell lung cancer, thereby enhancing the anticancer effect. By interfering with DNA synthesis and stimulating immune system, DMUP takes the advantage of chemotherapy and immunotherapy to inhibit cancer cells. The dual efficacy of DMUP makes it a potential chemoimmunotherapeutic agent in cancer therapy.
科研通智能强力驱动
Strongly Powered by AbleSci AI